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Hemodynamic instability during hemodialysis
Principal discussant: WILLIAM L. HENRICH
Dallas Veterans Administration Medical center and The University of Texas Health Science Center at Dallas, Dallas, Texas
A 77-year-old woman apparently was well until 2.5 years ago, when
she noted weight loss. Evaluation revealed a creatinine clearance of 8
mi/mm and a 24—hour urine protein excretion of 1.5 g. Urinalysis was
unremarkable. Renal ultrasound demonstrated bilaterally small kidneys
measuring 5.5 cm each. She also had severe kyphoscoliosis with
significant restrictive pulmonary disease. Her father and two brothers
allegedly had "Bright's disease" and her 45-year-old son had renal
insufficiency and hematuria. Deafness was prevalent in her family.
A diagnosis of chronic interstitial nephritis, probably due to Alport's
syndrome, was made and a thorough search for a remediable cause for
renal failure was unrevealing. Vascular access was created and she was
treated with a low-protein diet, phosphate-binding gels, sodium bicar-
bonate, calcium carbonate, 1 ,25-dihydroxycholecalciferol, and furose-
mide.
Hemodialysis was initiated 2 years ago because azotemia and uremia
became progressively more severe. Treatments have been carried out 3
times per week for 3 hours each, and a capillary flow Cuprophan
dialyzer, surface area 0.8 m2, has been used. The dialysate has
contained: sodium, 135; potassium, 2.0; calcium, 4.0; and acetate, 36
mEq/liter. The dialysate flow averages 500 mI/mm and blood flow
averages 244 mI/mm. Mean positive pressure is 120 mm/Hg and mean
negative pressure 27 mm Hg. Predialysis weight has averaged 45.1 kg
and postdialysis weight, 44.5 kg; the range of weights has been 43.5 to
47.5 kg. Average blood pressure has been 113/63 mm Hg prior to
dialysis, and 110/61 mm Hg at the end of dialysis. Transient hypoten-
sion, however, complicates approximately 50% of all the treatment
sessions; blood pressure frequently falls to 80/60 mm Hg and occasion-
ally to 70/40 mm Hg, the latter being associated with cramping and
vomiting. The patient's symptoms uniformly respond within 5 to 10
minutes to the intravenous administration of 100 to 200 cc of 0.9%, or
20 to 30 cc of 5%, saline; the blood pressure always returns to its
predialysis level by the end of dialysis.
Presentation of the Forum is made possible by grants from Pfizer
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Current medications include one teaspoon of aluminum hydroxide gel
after each meal; mineral oil as needed for constipation; one multivita-
mm daily; folic acid, I mg daily; and cyproheptadine HC1 (Periactin), 4
mg as needed for pruritis.
Discussion
DR. WILLIAM L. HENRICH (Chief, Renal Service, Dallas
Veterans Administration Medical Center, and Associate Pro-
fessor of Medicine, University of Texas Southwestern Medical
School, Dallas, Texas): This patient illustrates a persistent and
vexing problem associated with hemodialysis: frequent epi-
sodes of symptomatic hypotension. Hypotension occurs during
25% to 50% of dialysis treatments [1, 2]; newer treatment plans,
although useful in diminishing the frequency of hypotension,
have not eliminated it. Table 1 lists several factors that predis-
pose patients to hypotension during dialysis. Of the factors
listed that might be related to hypotensive epidsodes in this
patient, a decrease in cardiac reserve, autonomic insufficiency,
and a rapid decline in plasma osmolality during dialysis are
factors deserving special consideration.
In this review, I will analyze several aspects of the approach
to this clinical problem. First, I will present a brief overview of
autonomic dysfunction, a common disorder in dialysis patients
that, although usually not severe, is not easily treatable. Sec-
ond, I will review the importance of a stable plasma osmolality
during the dialysis procedure and methods of accomplishing
this. Finally, although I will not discuss all aspects of the
importance of diminished cardiac reserve, I will focus on the
influence of dialysate buffer on hemodynamics, either via
peripheral or cardiac effects. I will conclude with some specific
suggestions for this particular patient based on these consider-
ations.
Autonomic dysfunction
The incidence of autonomic dysfunction in dialysis patients is
considerable, affecting 50% of patients in one study [3]. The
presence and location of a defect in the autonomic nervous
system can be determined by performing a series of tests of the
autonomic nervous system (Table 2). The Valsalva maneuver is
performed by having the patient exhale against a closed glottis
(40 mm Hg) for 10 to 12 seconds; the physician then measures
the patient's heart rate (or the R-R interval on the electrocar-
diogram) and blood pressure following expiration [4]. The
Valsalva maneuver has been well standardized and examines
the integrity of the entire autonomic nervous system, that is,
both low and high pressure baroreceptors, the afferent pathway
to the central nervous system, and efferent sympathetic and
parasympathetic pathways. Thus, the Valsalva maneuver is
605
Editors
JORDAN J. COHEN
JOHN T. HARRINGTON
JEROME P. KASSIRER
NIcoLAos E. MADIAS
Managing Editor
CHERYL J. ZUSMAN
University of Chicago Pritzker School of Medicine
and
Tufts University School of Medicine
Case presentation
606 Neplirolegy Forum
Table 1. Factors predisposing to hypotension during hemodialysis
I. Decreased cardiac reserve
a. Coronary atherosclerosis
b. Hypertensive eardiomyopathy
c. ?Myocardial effects of acetate
d. Negative inotropic effects of antihypertensive medications
2. Autonomic insufficiency
3. Rapid decline in plasma osmolahty
4. Acetate's ability to decrease peripheral vascular resistance
(in approximately 10% of patients)
5. High ultrafiltration rates and rapid volume depletion
(particularly with short dialysis times and dialyzers > 1.5 m2)
6. Blood volume shift to dialyzer (200 300 ml)
useful in detecting an autonomic defect, but it does not localiLe
the defect as do the following two tests. The amyl nitrate test,
performed by having a patient inhale 3 breaths of an amyl
nitrate ampoule and then recording the blood pressure change
and heart rate or the R-R interval decrease on the EKO,
activates low pressure baroreceptors and the efferent sympa-
thetic arc [5, 6]. The cold pressor test, performed by placing the
patient's hand in ice slush for one minute, is a standardized test
of efferent sympathetic function. The cold pressor test results in
peripheral vasoconstriction and a 10 to 15 mm Hg increase in
blood pressure [7, 81. Hence a normal cold pressor test coupled
with an abnormal amyl nitrate test (or Valsalva maneuver)
would localize the defect to the haroreceptor/afferent limb of
the autonomic reflex arc, Methods of determining sensitivity of
the baroreceptors are also available.
A defect in the baroreceptor/afferent limb of the autonomic
arc has been the most consistent abnormality observed in
dialysis patients [8—li]. Nies and colleagues [91 demonstrated
that hypotension-prone dialysis patients had an abnormal re-
sponse to phenylephrine infusion, a test of baroreceptor sensi-
tivity [121. This finding, in combination with normal function of
the peripheral nervous system and the efferent autonomic
system, strongly suggests that the autonomic defect in most
dialysis patients resides in the baroreceptor/afferent limb.
Unfortunately, severe autonomic dysfunction is difficult to
treat. Usually, however, the defect is relatively mild and no
treatment is required. In those patients with severe autonomic
dysfunction, treatment is designed to maintain intravascular
volume, and sympathomimetic agents (such as ephedrine or
prostaglandin synthesis inhibitors) are ttscd. Elevation of the
head of the bed at night (to chronically increase circulating
angiotensin II levels) has been generally unrewarding. Some
patients with severe atitonomic deficits may ultimately require
the infusion of pressors during dialysis treatments.
Importance of a stable p/a coin o.cmolnlity
In the early days of dialysis, the dialysate sodium concentra-
tion was deliberately set low (hypoosmolar relative to plasma)
to avoid the problems of chronic volume overload in the patient
with total renal failure—most notably, hypertension and heart
failure. As the need for rapid volume loss became important
(because of shorter duration of dialysis), symptomatic hypotcn-
sion emerged as the most disahling routine problem during
dialysis. In the late 1970s, Wehle and coworkers made an
important observation [13]: they found that ultrafiltration alone
(in which isosmolar fluid is removed simply by exerting a
Table 2. Autonomic function tests
I. Valsalva maneuver (Ref. 4)
a. Patient exhales 40 mm Hg pressure against a closed glottis
for 10 to 12 seconds
b. Arterial pressure overshoot and a subsequent bradycardia
constitute a normal response
c. Tests high and low pressure baroreceptors, the affcrent
pathways to the CNS, and the efferent sympathetic and
parasympathetic pathways
2. Amyl nitrate inhalation (Ret. 6)
a. Patient inhales breaths of amyl nitrate gas from an
ampoule
F,. Measure the decrease in blood pressure (AP) and the
increase in heart rate (1-IR) that follows (or shortening of the
R-R interval on the EKCI); a normal response is
HR/AP 1.0
c. Tests low pressure baroreceptors and the efferent
sympathetic pathway
3. Cold pressor test (Ref. 8)
a. Patient places hand in ice water tbr one minute
b. Measure increase in blood pressure (usually 10—15 mm Hg)
and increase in heart rate (or decrease in the R R interval on
the EKO)
c. Primarily tests the efferent sympathetic pathway
transmembrane pressure across the dialyzer) could remove
large volumes and produce less hypotension than did regular
hemodialysis. The biochemical effects of ultrafiltration obvi-
ously differ from those of regular dialysis in several ways but,
among these, the fact that plasma osmolality remains stable
during the ultrafiltration procedure is critical. A decline in
plasma osmolality during regular dialysis favors fluid shift from
the extracellular volume to the intracellular volume, thereby
exacerbating any deliberate volume-depleting effects of dialy-
sis. Following the observations of Wehle et al on ultrafiltration,
it was discovered that maneuvers that increase plasma osmolal-
ity during dialysis are as effective as ultrafiltration in precluding
hypotension during dialysis [14]. The simplest way to increase
plasma osmolality during dialysis is to increase the sodium
concentration of the dialysate. A number of investigators have
shown marked improvement in hemodynamic tolerance to
acute dialysis if the dialysate sodium is increased, usually to a
concentration greater than 135 mEq/liter [15—221. The studies of
Van Stone and associates are particularly important because
these investigators documented a greater degree of plasma
volume depletion during hypotonic dialysis than during isotonic
or hypertonic dialysis [17]. Specifically, these investigators
noted a 20% reduction in plasma volume during hypotonic
dialysis compared with a 12% reduction during hypertonic
dialysis. Any decline in plasma volume, when combined with a
vasodilatory effect of acetate, would compound a tendency to
hypotension, because cardiac output also usually declines dur-
ing dialysis [23, 24].
Despite improvement in the heinodynamic tolerance during
acute dialysis with a higher sodium dialysate concentration,
several practical questions remained. The longer-term effects of
hypertonic dialysis—stimulated thirst and a greater interdialytic
weight gain—were potential hazards of such therapy [25—27].
Also important was the fact that any tendency to chronic
volume expansion would worsen hypertension or heart failure
[25, 28]. To evaluate the chronic effects of increased dialysate
sodium concentration on symptoms, weight gain, and blood
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pressure control, we performed a double-blind, 6-week cross-
over comparison of a high-sodium (144 mEq/liter) and a low-
sodium (132 mEq/liter) dialysate [291. In this study 10 stable
chronic dialysis patients were investigated. The use of the
higher-sodium dialysate resulted in fewer hypotensive episodes
(2.4 versus 8.0 episodes/patient/6 weeks, P <
.02); fewer bouts
of nausea, vomiting, and muscle cramping (6.0 versus 11.5
episodes/patient/6 weeks, P < .005); and reduced requirements
for intradialytic supplemental saline or mannitol (5.7 versus
15.0 treatments/patient/6 weeks, P <
.005) than with the lower-
sodium dialysate. As might be anticipated with the use of the
higher-sodium dialysate, both the beginning-of-the-week
plasma sodium concentration, 142 (high sodium) versus 140
(low sodium) mEq/liter (P < .02), and plasma osmolality, 316
(high sodium) versus 313 (low sodium) mOsm/kg H20 (P <
.005), were greater during the higher sodium dialysate protocol.
Similarly, mean interdialytic weight gains (2.3 versus 1.8 kg,
P <
.001) were greater in patients on the high-sodium protocol.
Weight loss on dialysis, however, was also greater during the
high-sodium protocol (2.4 versus 1.8 kg, P < .001) so that
postdialysis weights were comparable in both protocols. Predi-
alysis blood pressures were comparable during the two proto-
cols. These results demonstrate that the use of a higher-sodium
dialysate concentration is clearly associated with improved
blood pressure stability and general tolerance to dialysis. Our
results have been confirmed in other crossover trials [19, 30,
31].
Acetate versus bicarbonate as the dialysate buffer
Bicarbonate was used as the base in dialysis solutions in the
late l950s and early l960s, but its use required that 5% to 10%
CO2 be continuously bubbled through the dialysate to lower pH
and prevent the precipitation of calcium and magnesium salts.
This cumbersome system led to a search for a different buffer in
the early 1960s. Investigators were favorably impressed by the
fact that acetate is rapidly converted to bicarbonate at a rate of
300 mmol/hr in normal subjects [32]. This observation prompted
Mion, Hegstrom, Boen, and Scribner to conduct a successful
test of acetate dialysate in 6 patients [33]; since 1964, acetate
has become standard in dialysis baths. More recent reports
have suggested that the routine use of acetate might contribute
to adverse symptoms during dialysis. The symptoms most often
mentioned as complicating dialysis that have been attributed to
the inclusion of acetate are cardiovascular instability, hypoten-
sion, hypoxemia, abnormal lipid metabolism, and altered acid-
base status. These problems have been noted with even greater
frequency with the use of large-surface-area dialyzers [34, 35].I will briefly review the metabolism of acetate and then discuss
several important clinical trials in which acetate and bicarbon-
ate buffers have been compared.
Acetate traverses the dialysis membrane more slowly than
does bicarbonate; a dialysate concentration of 35 mmol thus is
required to exceed the mass transfer of bicarbonate from the
patient into the dialysate. Acetate is metabolized to acetyl CoA
primarily in muscle; its further metabolism to CO2 and water
consumes a hydrogen ion and thus generates a bicarbonate ion.
Since muscle is the primary site of metabolism of acetate, a
reduced muscle mass may reduce acetate metabolism. The
normal rate of acetate oxidation is 4.5 mmol/hr/kg in control
patients and 2.5 to 3.5 mmol/hr/kg in dialyzed patients. The
reduced metabolism of acetate reported in uremia and in older
individuals might be due in part to a reduction in muscle mass.
Obviously, the presence of hypot.ension also might impair
acetate metabolism by reducing blood flow to muscles. Most
acetate (approximately 90%) is converted to bicarbonate
[36—38]; the remainder, after conversion to acetyl COA, is
directed to fatty acid and cholesterol synthesis. Initially, there
was concern that acetate metabolism would cause hyperlipid-
emia and lead to accelerated atherosclerosis. However, neither
acute nor chronic studies have supported this concern [37, 39,
40].
The substitution of bicarbonate for acetate in dialysate has
been reported to improve patient tolerance, even in patients
who apparently metabolize acetate normally [35, 41, 42]. This
issue initially was investigated in the late l970s by Graffe et al,
who studied the responses of 6 patients known to be sympto-
matic on dialysis [43]. Large-surface-area dialyzers (2.5 m2)
were used; untoward symptoms were recorded in 24 of 27
acetate treatments but in only 6 of 29 bicarbonate dialyses (89%
versus 21%). Similar to the results of this study are the data of
Van Stone et al [44], who noted a higher incidence of symptoms
with acetate dialysis than with bicarbonate dialysis with both
regular and large-surface-area dialyzers.
Despite the association of acetate with a higher frequency of
symptoms in some studies, there is a poor correlation between
symptoms and signs and blood acetate concentrations [45—481.
Vinay et al, studying a large population of dialysis patients,
concluded that hyperacetatemia occurs in about 10% of the
dialysis population [491. This population of "intolerant" pa-
tients was predominantly female, again possibly reflecting re-
duced muscle mass. The presence of acetate "intolerance" was
reliably predicted by the absence of an increase in the serum
bicarbonate concentration following dialysis.
Acetate might act as a peripheral vasodilator, possibly by its
conversion to adenosine (via the action of 5'nucleotidase).
Some authors have noted a greater frequency of hypotension
with acetate dialysate than with bicarbonate dialysate [50—53];
in these studies, however, the dialysate sodium concentration
was below 140 mEq/liter. Other investigators, as I mentioned,
have not been able to link the use of acetate dialysate to
hypotension. For instance, in one study, 25% of the patients
had a rising and abnormal plasma acetate level during dialysis,
but they actually had fewer episodes of hypotension than did
patients with a normal plasma acetate concentration (the dial-
ysate sodium concentration was not given) [46]. Borges et al
also could find no difference in the incidence of hypotension in
30 patients with acute renal failure in a double-blind, crossover
study of acetate versus bicarbonate (dialysate sodium concen-
tration, 140 mEq/liter) [54]. A long-term study of chronic
dialysis patients by Castellani tested the putative advantages of
bicarbonate dialysis (standard surface area dialyzers; sodium
concentration, 140 mEq/liter for both acetate and bicarbonate)
[55]. Of the 20 patients studied, 9 had a history of repeated
episodes of hypotension on acetate dialysis. Hypotension de-
veloped in 46.8% of the acetate dialyses versus 41.9% of the
bicarbonate dialyses (NS).
How can these conflicting findings regarding dialysate buffer
be reconciled? Studies that have found vascular instability with
acetate dialysis [56—59] generally have found that the incidence
of hypotension is reduced if a higher sodium dialysate concen-
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Table 3. Approach to the hypoteusive dialysis patient
I. Assess aut000mic function
a. Valsalva maneuver
b. Amyl nitrate inhalation
c. Cold pressor tcst
2. Withhold antihypertensive agents prior to dialysis
3. Increase dialysate sodium eonecntration (140 to 145
mEq/liter)
4. Substitute bicarbonate buffer for acetate (most useful in
womcn and in patieuts with reduced muscle mass)
5. Try ultrafiltration initially (to achieve weight loss needs)
followed by isovolemic, high-sodium, bicarbonate dialysis
tration is employed. in one of our studies [58], palients
screened to determine whether significant autonomic dysfunc-
tion was present were then dialyzed against a high sodium (140
mEq/liter) or low sodium (130 mEq/liter) bath. With the low-
sodium acetate dialysate, patients with autonomic insufficiency
had a significant fall in upright blood pressure after dialysis;
further, all patients (with and without autonomic dysfunction)
had a greater frequency of orthostatie symptoms after acetate
dialysis when compared to the low-sodium bicarbonate dialy-
sate. With the high-sodium dialysates, patients with autonomic
insufficiency had a greater incidence of symptoms than did
patients without autonomic nervous system dysfunction, but
the incidence was not significantly different between acetate
and bicarbonate dialysates. With the high-sodium dialysate.
mean blood pressure, cardiac output, and postdialysis ortho-
static changes in blood pressure were similar with bicarbonate
and acetate baths. In summary, the most important causative
factor for the hypotensive episodes appeared to he the dialysate
sodium concentration, as a high dialysate sodium concentration
ablated the improvement noted with bicarbonate (and low-
sodium) dialysate.
Another mechanism by which acetate might provoke hypo-
tension is via a direct effect on myocardial performance. Early
animal studies had suggested that acetate impaired myocardial
contractility. Kirkendol and colleagues gave dogs intravenous
boluses of acetate and noted that it was a myocardial depressant
[60]. in a later study, however, Kirdendol et al questioned this
finding [61]. Human studies have not settled the issue of direct
myocardial effects of acetate. Aizawa and coworkers compared
cardiac function pre- and post-acetate and/or bicarbonate
hemodialysis with phonocardiography and concluded that myo-
cardial function was more depressed after acetate than after
bicarbonate dialysis [62]. More recently Ruder et al studied 36
patients with both a normal and a low baseline velocity of
circumferential shortening (Vef, an index of myocardial con-
tractility) using echocardiography 163]. In the patients with a
depressed Vcf, hemodialysis with either buffer resulted in
improvement of ventricular function (bicarbonate dialysate
greater than acetate). In patients with a normal Vcf, only
bicarbonate dialysis produced significantly better ventricular
function. In contrast to these studies, which suggest at least
some beneficial effect of bicarbonate dialysate over acetate,
other investigators have been unable to show an improvement
with bicarbonate dialysate [64, 65].
One major difficulty in evaluating the effects of any dialysate
composition on cardiac function results from the failure to
distinguish the effects of hemodialysis per se from the effects of
volume removal. My colleagues and I investigated this problem
in a group of hemodialysis patients not taking cardiac or
antihypertensive medications [66]. Three maneuvers were em-
ployed in the study: regular dialysis (acetate dialysate), ultra-
filtration (volume removal) only, and dialysis (acetate dialysate)
without weight loss. By plotting ventricular performance over
several filling volumes, we concluded that ultrafiltration alone
(volume removal) produced a pure Frank-Starling effect (a
decrease in cud-diastolic volume), whereas acetate hemodi-
alysis (toxin removal) with or without volume loss produced an
increase in contractility, in effect an upward shift of the
ventricular function curve. Mchta et al also found a similar
positive inotropic effect with comparable improvements in
cardiac function with acetate and bicarbonate dialysate [67].
We have studied 5 stable patients with both acetate and
bicarbonate dialysis at 3 different cardiac filling volumes before
and after isovolemic dialysis (randomized, double-blinded,
crossover study) and found a similar improvement in cardiac
function under these conditions with both baths [68]. These
studies suggest that in most chronic, stable dialysis patients
with reasonable cardiac function (assessed by EKO, history,
and physical examination), both acetate and bicarbonate dialy-
sates are associated with improved cardiac performance.
It is clear that Graffe and colleagues' initial report of im-
proved tolerance to weight loss with bicarbonate dialysis [43]
has been a catalyst in stimulating the investigation of bicarbon-
ate versus acetate dialysate. Overall, the ensuing studies have
produced conflicting results, demonstrating a clear-cut benefit
with the use of a bicarbonate bath only in certain circum-
stances. Specifically, bicarbonate dialysate seems most con
vincingly beneficial only when a low-sodium dialysate concen-
tration (less than 135 mEq/liter) is used. In addition, recent
studies have identified a minority of patients who are genuinely
"acetate-intolerant"; in Vinay's large study, these patients
comprise approximately 10ff of the dialysis population [49].
Currently bicarbonate dialysis is more costly than is acetate
dialysis. For example, in a unit where each individual dialyzer
mixes the dialysate, the cost of converting each machine from
an acetate-only dialysis manifold to a system capable of bicar-
bonate dialysis costs approximately $2200 (for a Drake-Willock
machine). tn addition, the cost of individual treatments with
bicarbonate is greater than that for acetate dialyses (about $4.50
for pre-mixed acetate dialysate versus about $7.50 for pre-
mixed, dry-pack bicarbonate dialysate in our institution). In
dialysis units with central mixing systems, bicarbonate treat-
ments also are more expensive. The initial equipment outlay
will likely cost 25% to 50% more. Maintenance is more costly,
and individual dialysis treatments are more expensive, in cen-
tral batching systems ($2.00 to $2.50 per acetate treatment
versus $2.75 to $3.25 per bicarbonate treatment), although the
cost differential is small (cost data provided by National Med-
ical Care, personal communication).
Approach to the hypotcnsn'c patient
Based on this analysis (see Table 3), my approach to the
problem in today's patient, who has frequent bouts of hypoten-
sion, would he first to increase the dialysate sodium concentra-
tion to 140 to 142 mEq/litcr. She is likely to have reduced
muscle mass (because she has renal failure, is elderly, and is
female), and therefore probably would be in the subgroup
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postulated to most benefit from bicarbonate dialysate. Thus, if
the higher-sodium dialysate failed to reduce the hypotensive
episodes to an acceptable level, the use of a bicarbonate
dialysate would be a reasonable second step. Finally, if these
two maneuvers in combination failed, I would suggest ultrafil-
tration for an hour followed by high-sodium, bicarbonate dial-
ysis in which no transmembranepressure was applied. If none
of these steps sufficiently ameliorated her symptoms, alterna-
tive options, such as continuous ambulatory peritoneal dialysis,
must be considered.
Questions and answers
DR. JAMES BOURDEAU (Renal Division, Michael Reese Ilos-
pital, Chicago, Illinois): You suggested that the improvements
in cardiac performance observed during and following dialysis
might be due to changes in the serum concentration of ionized
calcium. Have you made measurements to investigate this
possibility?
DR. HENRICH: Yes. In a recent study we related the increase
in the Vcf to an increase in the ionized calcium concentration
(from 4.4 to 5.4 mg/dl, P<.OOl) [691. I did not present those data
today. Although the increase in Vcf was most closely linked to
changes in the ionized calcium concentration, other factors
(such as a concomitant decline in magnesium and potassium
concentrations) also might play a role.
DR. SUSAN FELLNER (Renal Section, Mitchell Hospital,
Chicago): Were ionized calcium and catecholamine levels mea-
sured in the crossover study in which bicarbonate and acetate
dialysis were compared?
DR. HENRICH: We measured total calcium concentration, but
norepinephrine levels were not measured in that particular
study. In a prior study from our center [141, norepinephrine
concentrations were high before dialysis in the dialysis patients
and increased slightly during ultrafiltration dialysis.
DR. FELLNER: In some centers, a subset of the chronic
dialysis population also suffers from chronic alcoholism. Do
you think the presence of severe liver disease in this group
contributes to a reduced capacity to metabolize acetate?
DR. HENRICH: Possibly. However, Vinay reported that the
predominant factor in slow acetate metabolism appeared to be
a reduction in muscle mass [49].
DR. ARNOLD BERNS (Attending Nephrologist, MichaelReese
Hospital): Can you predict acetate intolerance simply by look-
ing at the predialysis bicarbonate concentration? Do acetate-
intolerant patients maintain a lower serum bicarbonate concen-
tration than do patients who are acetate tolerant?
DR. HENRICH: Vinay and colleagues derived a formula for
predicting acetate intolerance on the basis of the change in
predialysis plasma bicarbonate concentration compared with
the postdialysis plasma bicarbonate concentration [491. Ace-
tate-intolerant patients had either no change or a small change
(i to 2 mEq/Iiter) in the plasma bicarbonate concentration
during dialysis.
DR. JORDAN J. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital): You noted the relatively high inci-
dence of autonomic dysfunction in dialysis patients, which
presumably is due to defects in afferent baroreceptor mecha-
nisms. I assume this incidence is much higher than that ob-
served in an age-matched, non-dialysis-dependent population.
What is it about end-stage renal disease or about dialysis that
produces autonomic dysfunction?
DR. HENRICH: Perhaps the frequent history of hypertension
contributes to the defect in these patients. Another possibility is
the presence of a factor related to uremia. As far as I know, no
systematic investigations have successfully associated the pres-
ence of autonomic dysfunction with a factor in uremia. Another
aspect of the problem is the large number of new dialysis
patients who are diabetics. These patients would seem to be at
increased risk for autonomic dysfunction, but they may exhibit
a combined pattern of abnormalities: that is, both baroreceptor
and efferent dysfunction. Other unanswered questions relate to
the progression of the autonomic dysfunction in dialysis pa-
tients: Does it grow worse with time? Can it be related to some
factor in renal failure, such as hypertension, inadequate dialy-
sis, or parathyroid hormone concentration?
DR. COHEN: Is there any correlation between the incidence
or severity of the autonomic nervous system defect and the
duration of dialysis? Second, does the incidence or severity of
the defect differ between patients treated with chronic perito-
neal dialysis and those treated with chronic hemodialysis?
DR. HENRIcH: As far as I know, these issues have not been
studied.
DR. SHELDON HIRSCH (Renal Fellow, University of Chi-
cago): Do patients who have frequent hypotensive episodes
during dialysis fare any worse over the long term than do those
who do not have such episodes?
DR. HENRIcH: I do not know whether the mortality rate
increases dramatically, but clearly the morbidity of the proce-
dure is substantially worse. One of the major goals of dialytic
therapy is some degree of rehabilitation, and this problem
thwarts those efforts.
DR. COHEN: You observed during your crossover study of
high-sodium versus normal-sodium dialysate that the sodium
concentration remained somewhat elevated at the time of the
next dialysis, 2 or 3 days later. You commented that the
persistence of mild hypernatremia evidenced a persistent
dipsogenic stimulus. I would have thought that if a dipsogenic
stimulus had persisted, sufficient time would have elapsed for it
to have resulted in adequate water ingestion and in a return of
plasma osmolality and sodium concentration back to normal. I
think one could make a case that the persistent hypernatremia
evidenced a blunted dipsogenic response rather than a persist-
ent one.
DR. HENRIcH: The patients with a mild increase in sodium
concentrations did gain more weight, so we assumed they
ingested more fluid. Some patients actually said that they were
more thirsty and admitted having consumed more fluid during
the interdialytic period. Obviously they did not correct plasma
osmolality, which suggests some blunting of the dipsogenic
stimulus.
DR. COHEN: You noted that hypertensive patients might run
some risk when dialyzed against a high-sodium dialysate. Is it
the elevated serum sodium concentration that is of concern, or
the risk of positive sodium balance? If it is the latter, I would
have thought that one could avoid positive sodium balance
simply by appropriately adjusting the ultrafiltration rate.
DR. HENRICH: We were able to successfully remove the extra
weight that our patients gained in the interdialytic period in the
high-sodium phase of the crossover trial [29]. Predialysis blood
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pressures were comparable in both the high-sodium and low-
sodium phases of the study. If hypertension had occurred, I
would have related it to positive sodium balance and to an effect
on extracellular volume expansion. I should mention, however,
that I do think that there are patients who do not tolerate
higher-sodium dialysates. These patients exhibit tendencies to
hypertension, pulmonary edema, and excessive interdialytic
weight gains. I think a higher-sodium dialysate must be tested
individually.
DR. MARK RICHTER (Renal Fellow, University of Chicago):
Regarding the data you reviewed about ambulatory patients
treated with chronic hemodialysis: What do you recommend for
patients with acute renal failure who require dialysis? Do you
use bicarbonate or acetate dialysis in this setting?
DR. HENRICH: One might predict that acute hemodialysis is a
setting in which bicarbonate dialysate would be more advanta-
geous than acetate dialysate because of the inherent instability
of that group of patients. There is at least one negative study on
this subject [541 but, as with many studies of acute renal failure,
matching patient groups is a difficult task. We currently employ
bicarbonate dialysate for our more catabolic patients, but we
have not systematically examined this question in the setting of
acute renal failure.
DR. PAUL SACKS (Renal Fellow, University of Chicago):
Would you comment on the use of hypothermic dialysate to
reduce the frequency of symptomatic hypotension in patients
refractory to more conventional measures?
DR. HENRICH: Maggiore and colleagues have reported
greater hemodynamic stability in hypotension-prone patients
when the dialysate is cooled to 34.5°C [70]. The mechanism of
this protection has not been elucidated, but it deserves further
investigation. The safety and efficacy of this procedure also
need to be tested more extensively.
DR. SUSAN HOU (Renal Divtcion, Michael Reese Hospital):
What is your experience with methods other than high-sodium
dialysate to increase serum osmolality? I have in mind, for
example, the infusion of hypertonic glucose, which increases
osmolality but, because the glucose is metabolized, does not
leave the osmolality high for days after the dialysis.
DR. HENRICH: I do not have any experience with hypertonic
glucose as a protection against hypotension. The only
hypertonic solutions we have used are mannitol, albumin, and
saline. Theoretically, an infusion of hypertonic glucose should
be of some benefit if it raises osmolality. Do you use hypertonic
glucose routinely?
DR. Hou: Yes, we do. I think all of us who care for dialysis
patients use some agent or agents such as hypertonic mannitol,
hypertonic sodium chloride, or 50% dextrose as part of our
dialysis witchcraft. But has anyone looked at the results of
these interventions in a formal way as you have for high- versus
low-sodium dialysis?
DR. HENRICH: We have examined the mechanism of blood
pressure protection with mannitol, ultrafiltration, and differing
dialysate sodium concentrations, but we have not tested
hypertonic glucose.
DR. COHEN: Is using bicarbonate dialysate inherently more
expensive than using acetate dialysate? Bicarbonate is a smaller
molecule than acetate; you would think it would be cheaper!
DR. HENRICH: The differences in cost of the two systems
relate to the fact that bicarbonate dialysate requires two pumps
in the individual proportioning units we utilize. Essentially,
there are two machines in one, As for the bicarbonate dialysate
being inherently more expensive, the cost differences between
the two dialysates have narrowed in recent years. As I men-
tioned earlier, the costs of the two systems are not large if a
central batching system is to be installed new. Maintenance
costs are said to be comparable.
Reprint requests to Dr. W. Henrich. Chief Nephro/ogy Service, The
University of Texas Health Science Center cit Dallas. Dallas Veterans
Adrnintstration Medical Center, 4500 S. Lancaster Road, Dallas, Texas
752/6, USA
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